The Chinese traditional herb Tripterygium wilfordii Hook f (TwHF) has been widely used in the treatment of autoimmune and inflammatory diseases. Over the past few decades, great efforts have been made to explore modern preparations of TwHF with higher efficacy, solubility, and lower toxicity. In this study, we reviewed several examples both of naturally occurring compounds and their derivatives in TwHF, and summarized the preclinical evaluations with regard to autoimmune and inflammatory diseases. All of the candidate compounds described herein have been or are currently in clinical trials. Although some studies encountered problems, the data still provided valuable references for future studies. (5R)-5-hydroxytriptolide (LLDT-8, Leitengshu) is a novel triptolide derivative with potent immunosuppressive and anti-inflammatory activities developed at Shanghai Institute of Materia Medica. Indeed, a Phase I clinical trial for this compound has been completed in rheumatoid arthritis patients. The results will provide the basis for the further exploration of this ancient herb and encourage the research and development of valuable traditional Chinese medicine. 
Introduction
For thousands of years, natural products have played an important role throughout the world in treating and preventing human diseases [1] [2] [3] [4] [5] . The discovery and development of immunosuppressants from natural sources have an impressive record: mycophenolic acid (MPA) and cyclosporin A (CsA), the fungal metabolites isolated in 1932 [6] and 1970 [7] , respectively; rapamycin, found in 1975 [8] ; FK506, extracted from a culture filtrate of Streptomyces tsukubaensis in 1987 [9, 10] ; and fingolimod (FTY720), described in 1995 [11] . Although the current industry model for drug discovery does not favor natural products, the resources are so vast as to seem unlimited, and these emerging tools will provide important discoveries, leading to new medicines [12] . Furthermore, the drugs already in use as immunosuppressants (eg, cyclophosphamide, methotrexate, azathioprine, cyclosporin) are associated with some significant problems, including toxicity, a lack of reversibility, and increased susceptibility to viral and other infections [13] . Indeed, exploring new and innovative immunosuppres-sants from natural sources has now become a focus of intense research.
Tripterygium wilfordii Hook f (TwHF) and its extracts have been widely used in the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM) [14] [15] [16] [17] [18] , and have beneficial effects on tissue and organ transplantation [19, 20] . In 1993, the ethyl acetate (EA) extract of TwHF was entered into a Phase I study for the treatment of RA patients [21] [22] [23] [24] [25] , and many clinical trials have tested triptolide for the treatment of RA and psoriasis [26, 27] . In addition, PG490-88/F60008 (Figure 1 ), a water-soluble prodrug of triptolide, has been approved for entry into a Phase I clinical trial for the treatment of solid tumors [28, 29] . The Shanghai Institute of Materia Medica (SIMM) has made great efforts to discover drugs from natural products that are of clinical value and have contributed to the treatment of autoimmune diseases, such as RA, SLE, and multiple sclerosis (MS). By combining basic and applied research efforts and through the collaboration between chemistry and biology, the SIMM has developed several series of immunosuppressive drug candidates against autoimmune diseases: LLDT-8 ( Figure  1 ), a novel triptolide analog from the Chinese traditional herb TwHF, that will enter into a Phase II clinical trial involving RA patients in China [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] ; SM934, a water-soluble derivative of artemisinin; and periplocoside E, a pregnane glycoside identified from Periploca sepium Bge.
This review focuses on the drug candidates isolated from TwHF. Regardless of the success or failure in treatment, the experience gained through the exploration and practice is invaluable.
TwHF, a representative Chinese medicinal herb showing immunosuppressive and anti-inflammatory activities
TwHF is a deciduous climbing vine that grows up to 12 meters and has brown, angular, downy twigs. The leaves are light green, smooth adaxially, and pale gray with light-colored hairs abaxially. As a well-known Chinese medicinal herb, TwHF is distributed widely in southern China, including Fujian, Zhejiang, and Anhui Provinces. The Chinese herb Lei Gong Teng is derived from the roots of TwHF and has been used in traditional Chinese medicine for more than two thousand years. The description of TwHF has been traced to the period of the Three Kingdoms (220-280 AD) when these plants were recorded as "Mangcao" For centuries, Chinese people have used TwHF and its extracts for the treatment of autoimmune and inflammatory diseases, including RA, SLE, and DM. Contemporary researchers have attempted to standardize the TwHF extract for further development and investigate its efficacy in autoimmune diseases, and some progress had been achieved in recent years. The ethyl acetate (EA) extract of TwHF was entered into a Phase I study that included 13 patients with established RA in 1993 [21] [22] [23] [24] [25] . The EA extract of TwHF at dosages up to 570 mg/d appeared to be safe, and doses >360 mg/d were associated with clinical benefits in the patients with RA [21] . The dosage was normalized to previous extracts by assessing the content of triptolide and tripdiolide. A randomized, controlled, 24-week study was then conducted in 2004 in patients with active RA and 6 or more painful and swollen joints [22] . The results demonstrated that the treatment with a standardized extract from the peeled roots of TwHF administered (60 mg 3 times daily) over 24 weeks may be both effective and safe in treating patients with active rheumatoid arthritis.
With the recent technological developments in the isolation and structural identification of compounds, more than 100 components have been isolated from TwHF, with most of them having a potent therapeutic efficacy for a variety of autoimmune and inflammatory diseases. Among the reported active components from this herb, including triterpene, diterpene and macrocyclic alkaloids, the most noteworthy component is triptolide. Triptolide, an oxygenated diterpene, was identified as the most active component, accounting for the immunosuppressive effects of TwHF [41, 42] . Over the past few decades, much research has been conducted on the clinical use of triptolide for the treatment of autoimmune and inflammatory diseases, such as RA, SLE, nephritis [26, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] , psoriasis [27] , and Crohn's disease [53] , and kidney transplantation [54] . However the strong toxicity, particularly with regard to male reproductive toxicity, limits the application of triptolide to a great extent [55] [56] [57] [58] . To identify more effective compounds with less toxicity and higher solubility, the structural modification of triptolide was studied, and derivatives were synthesized and evaluated for their biological activities. In the past few years, new watersoluble triptolide derivatives have been designed and synthesized, including PG490-88 or F60008. PG490-88 or F60008, a prodrug of triptolide, is converted to triptolide in vivo by plasma esterases following intravenous administration [59] [60] [61] [62] [63] [64] [65] [66] [67] . Table 1 summarizes the preclinical pharmacological study of triptolide and PG490-88/F60008 against autoimmune diseases and transplantation rejection. Although PG490-88 or F60008 has been approved for entry into a Phase I clinical trial for the treatment of solid tumors, two lethal events were observed in twenty patients, and the high inter-individual variability rendered PG490-88 or F60008 a far from optimal derivate of triptolide [28, 29] . [31] . Over the course of ten years, the biological activity of LLDT-8 has been evaluated, and the underlying mechanisms have been investigated with regard to many autoimmune and inflammatory diseases. The administration of LLDT-8 reduced the incidence and severity of collagen-induced arthritis in DBA/1 mice [33] . To assess the long-term effectiveness of LLDT-8, 3-month-treatment experiments were performed. The oral administration of LLDT-8 (0.125, 0.25, and 0.5 mg/kg, starting at 1 d before the booster immunization) consistently attenuated the severity of CIA compared with untreated mice. LDP, Leigongteng Duodai Pian, is the prescription drug of the extracts of TwHF used for treating RA in China. The preventive effect of LLDT-8 at a dose of 0.25 mg/kg was similar to LDP at 20 mg/kg in CIA mice. We also tested the therapeutic effect of LLDT-8 after the establishment of RA, and the inhibitory profile was persistent during the 3-month observation. LLDT-8 also exerted therapeutic effects on experimental autoimmune encephalomyelitis (EAE) [36] , concanavalin A-induced acute hepatitis [37] , graft-versus-host disease (GVHD) [32] , allograft rejection [38] , and bleomycin-induced lung fibrosis [39] . LLDT-8 effectively inhibited human T cell immune responses without affecting the NK cytotoxic activity, and this immunosuppressive activity was parallel to that observed for murine immunity [40] . The mechanism of LLDT-8 involves a variety of immune cells and molecules and includes limiting T cell function and proliferation, inhibiting macrophage activation, inducing regulatory T cell expansion, and interfering with IFN-γ-related signaling [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . More importantly, compared to triptolide, LLDT-8 displayed a much lower toxicity both in vitro and in vivo. The CC 50 value of LLDT-8 was 256.6±73.8 nmol/L, and the CC 50 value of triptolide was 2.1±0.3 nmol/L in murine splenocytes. The immunosuppressive effects of LLDT-8 and triptolide were also tested in mitogen-and alloantigen-induced lymphocyte proliferation assays. The IC 50 values of triptolide for inhibiting ConA-induced T lymphocyte proliferation, LPS-induced B lymphocyte proliferation, and mixed lymphocyte reaction (MLR) were 6.7±0.2, 8.6±2.8, and 2.7±0.6 nmol/L, respectively, with the IC 50 values of triptolide being close to or even higher than the CC 50 values. This result indicated that the activities of triptolide were largely dependent on its cytotoxicity. However, the IC 50 values of LLDT-8 for inhibiting the lymphocyte proliferation caused by ConA, LPS, or MLR were lower than its CC 50 values (IC 50 =131.7±32.4, 171.5±17.3, and 38.8±5.1 nmol/L, respectively), thus excluding the possibility that the inhibitory activities of LLDT-8 were attributable to its cytotoxicity [31] . When administered in mice, the lethal dose for 50% of the animal test population of LLDT-8 is 9.3 mg/kg (intraperitoneal), whereas that of triptolide is 0.86 mg/kg, with a 10-fold lower acute toxicity in vivo [30] . Table 2 summarizes the preclinical pharmacological study of LLDT-8 as an immunosuppressant drug candidate. Female RA patients who were over the 35 years of age and menopausal or did not have birth demands were enrolled in a tolerability and pharmacokinetic study. The tolerability and pharmacokinetic properties of LLDT-8 and its initial therapeutic efficacy were assessed and determined. According to the pharmacokinetic and pharmacodynamic results reported using experimental animals, the initial dose should be set at 0.25 mg/d. In accord with the dose escalation scheme, the highest dose could be set at 4 mg/d in the phase I clinical trial for LLDT-8 [30] . The results of the clinical trial will provide the basis for the further exploration of this novel derivate of triplide and encourage the research and development of valuable traditional Chinese medicine.
Concluding remarks
Research on TwHF has long been an intense issue. During the past few decades, several drug candidates from this herb have been or are currently in clinical trials. However, it has been demonstrated that some compounds cannot be considered the optimal derivative of triptolide. For other compounds, for example, LLDT-8, we are still awaiting the results of the clinical studies. Regardless of the results of the trials, research on this important ancient medicinal herb will continue. Significant delay in time to onset of arthritis, as well as significantly decreased arthritis incidence, clinical arthritis severity score, histopathological arthritis severity score, and in vivo cell-mediated immunity to collagen Arthritis incidence was reduced in all groups after receiving triptolide (8-32 μg/kg), arthritis scores was suppressed at 16 and 32 μg/kg doses Thickness index decreased in all administration groups and maximal inhibition occurred at a dose of 0.4 mg/kg Prevented GVHD induction and development, produced long-term survival
The median survival time (MST) was 8 d for placebo; 9. 
